- Home
- / Oncopeptides
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Oncopeptides financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
KR2.2
2024-09-27
Market Capitalization
KR462.7 M
2024-09-27
Revenue
KR35.2 M
FY, 2023
CreditSafe Score
?
Score changed on Oct 11, 2024
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| SEK | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 118.3M | 8.4M | 35.2M | |||
| Cost of goods sold | 31.8M | 6.0K | (1.1M) | |||
| Gross profit | 10.1M | 8.3M | 158.1M | 14.4M | 42.6M | |
| Gross profit margin, % | 133.6% | 172.2% | 121.1% | |||
| Operating expense total | 420.7M | 743.2M | 1.6B | 1.6B | 346.6M | 284.4M |
| Depreciation and amortization | 346.0K | 4.5M | 14.4M | 21.4M | 17.2M | 11.0M |
| EBITDA | (410.6M) | (734.9M) | (1.6B) | (1.4B) | (332.2M) | (241.7M) |
| EBITDA margin, % | -1183.1% | -3975.7% | -686.4% | |||
| EBIT | (411.0M) | (739.4M) | (1.6B) | (1.4B) | (349.4M) | (252.8M) |
| EBIT margin, % | -1201.2% | -4181.3% | -717.7% | |||
| Interest income | 322.0K | 492.0K | 2.6M | 8.6M | ||
| Interest expense | 2.0K | 528.0K | 1.5M | 948.0K | 883.0K | 5.8M |
| Pre tax profit | (411.0M) | (739.9M) | (1.6B) | (1.4B) | (337.7M) | (248.4M) |
| Income tax expense | 147.0K | 785.0K | 2.3M | 8.9M | 271.0K | 664.0K |
| Net Income | (411.1M) | (740.7M) | (1.6B) | (1.4B) | (338.0M) | (249.1M) |